Bokf Na Raises Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• Bokf Na increased its stake in Gilead by 9.6% to 113,756 shares (worth about $12.63M) in Q3, in a stock that is 83.67% institutionally owned.
• Insiders have been net sellers — CEO Daniel Patrick O'Day sold 115,640 shares (~$15.6M) and insiders disposed of 309,280 shares (~$43.9M) in the past 90 days, leaving insiders with 0.27% ownership.
• Gilead beat quarterly estimates with $1.86 EPS and $7.93B revenue, set FY2026 guidance at $8.45–$8.85 EPS, and raised its quarterly dividend to $0.82 (2.2% yield).

Bokf Na grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 113,756 shares of the biopharmaceutical company's stock after purchasing an additional 9,926 shares during the quarter. Bokf Na's holdings in Gilead Sciences were worth $12,627,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Trivium Point Advisory LLC raised its stake in Gilead Sciences by 1.1% in the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company's stock worth $813,000 after buying an additional 83 shares in the last quarter. Rothschild Investment LLC boosted its position in Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company's stock valued at $503,000 after acquiring an additional 84 shares in the last quarter. Hemington Wealth Management grew its holdings in shares of Gilead Sciences by 9.3% during the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company's stock worth $110,000 after acquiring an additional 85 shares during the period. Ignite Planners LLC grew its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company's stock worth $880,000 after acquiring an additional 86 shares during the period. Finally, Archer Investment Corp raised its position in shares of Gilead Sciences by 1.2% in the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company's stock worth $807,000 after acquiring an additional 87 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 115,640 shares of the business's stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares of the company's stock, valued at approximately $76,504,230. The trade was a 16.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the sale, the insider directly owned 120,288 shares in the company, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 309,280 shares of company stock valued at $43,935,470. Company insiders own 0.27% of the company's stock.

Gilead Sciences Trading Down 1.7%

NASDAQ:GILD opened at $146.00 on Thursday. The stock has a market cap of $181.25 billion, a price-to-earnings ratio of 21.57, a PEG ratio of 1.95 and a beta of 0.37. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The company's 50 day moving average price is $139.70 and its 200-day moving average price is $126.44. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm's revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, March 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 46.68%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Jefferies initiated coverage with a Buy and $180 price target, signaling analyst confidence and implying ~23% upside from recent levels. This provides fresh institutional buy-side interest. Jefferies Starts Gilead Sciences at Buy
• Positive Sentiment: Short interest fell ~15.7% in February to ~18.45M shares (1.5% of float), lowering the potential for short-squeeze volatility and suggesting fewer immediate bearish bets against the stock. Market data on GILD short interest
• Positive Sentiment: Macro/sector tailwind: commentators including Josh Brown (Ritholtz) are bullish on large-cap biotech as a growth segment less prone to disruption, which supports investor appetite for Gilead as a defensive growth name within biotech. Josh Brown: Biotech growth stocks immune to disruption risk
• Positive Sentiment: Market opportunity: industry reports point to expansion in CD19-targeted therapies and autoimmune/oncology pipelines, which underpins the strategic rationale for Gilead’s moves to build out oncology/CAR-T capabilities. CD19 Inhibitors Market to Witness Significant Expansion
• Neutral Sentiment: Investor outreach: Gilead presented at the Barclays and Leerink healthcare conferences (transcripts available); these investor events provide detail but have not produced a clear immediate market reaction. Barclays conference transcript
• Neutral Sentiment: Recent trading: coverage roundup and prior-day outperformance show momentum, but the move may invite short-term profit-taking. Gilead Outperforms Broader Market
• Negative Sentiment: Acquisition concern: Gilead agreed to buy Arcellx for up to $7.8B at roughly a 79% premium to the pre-deal price — strategic for oncology/CAR-T scale but potentially dilutive/expensive in the near term, which can pressure sentiment and trigger selling from valuation-conscious investors. Gilead to Acquire Arcellx, Inc. for Up to $7.8 billion

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on GILD shares. Truist Financial raised their target price on Gilead Sciences from $145.00 to $152.00 and gave the company a "buy" rating in a research note on Wednesday, February 11th. Leerink Partners upped their price target on Gilead Sciences from $146.00 to $148.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 11th. HSBC raised their price objective on Gilead Sciences from $110.00 to $133.00 and gave the company a "hold" rating in a research report on Wednesday, December 10th. Wall Street Zen downgraded shares of Gilead Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, January 23rd. Finally, Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Twenty-four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $157.62.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.